KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA Acquisition strengthens Servier’s neurology pipeline in line ...
Servier has agreed to acquire Medicxi company Kaerus Bioscience's potential Fragile X syndrome (FXS) treatment, KER-0193. Servier will pay Kaerus Bioscience upfront, with additional development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback